| 参考文献: |
1. Alberto Bessudo, et al. A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.2. Reuveni H, et al. NT219, a dual inhibitor of IRS1/2 and STAT3, suppresses cancer stem cell-mediated resistance to KRASG12C and KRASG12D inhibitors in solid tumors[J]. cell, 2024, 3(2): 1.3. Reuveni H, et al. NT219, a novel dual inhibitor of STAT3 and IRS1/2, demonstrates anti-tumor activity with and without cetuximab in pembrolizumab-resistant head and neck cancer PDX models[C]//Cancer Research. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2020, 80(16). |